<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788541</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-049</org_study_id>
    <nct_id>NCT00788541</nct_id>
  </id_info>
  <brief_title>A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the effects of total volume and total dose on the
      safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and
      48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD)
      for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
      or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Project cancellation
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients who remain rescue-medication free</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>3 mg Anecortave Acetate, low volume high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg Anecortave Acetate, high volume low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 mg Anecortave Acetate, low volume high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 mg Anecortave Acetate, high volume low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate Vehicle, low volume</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate Vehicle, high volume</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 6 mg/mL</intervention_name>
    <description>Administered as an injection into an anterior juxtascleral depot</description>
    <arm_group_label>3 mg Anecortave Acetate, low volume high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 3.75 mg/mL</intervention_name>
    <description>Administered as an injection into an anterior juxtascleral depot</description>
    <arm_group_label>3 mg Anecortave Acetate, high volume low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 96 mg/mL</intervention_name>
    <description>Administered as an injection into an anterior juxtascleral depot</description>
    <arm_group_label>48 mg Anecortave Acetate, low volume high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 60 mg/ML</intervention_name>
    <description>Administered as an injection into an anterior juxtascleral depot</description>
    <arm_group_label>48 mg Anecortave Acetate, high volume low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anecortave Acetate Vehicle</intervention_name>
    <description>Administered as an injection into an anterior juxtascleral depot</description>
    <arm_group_label>Anecortave Acetate Vehicle, low volume</arm_group_label>
    <arm_group_label>Anecortave Acetate Vehicle, high volume</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Open-Angle Glaucoma or Ocular Hypertension for at least 6
             months;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Prior angle surgery in the study eye, severe visual field loss in either eye;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <disposition_first_submitted>November 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 30, 2012</disposition_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-Angle Glaucoma</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Anecortave Acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

